Intensive Pre-Operative Radiotherapy for Soft Tissue Sarcoma
(PRESTO Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new radiation treatment for patients with localized soft tissue sarcomas. The treatment uses higher doses of radiation to be more effective and quicker, potentially reducing surgery delays and complications.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is hypofractionated radiotherapy safe for soft tissue sarcoma patients?
Research shows that hypofractionated radiotherapy, a shorter and more intense form of radiation treatment, is generally safe for patients with soft tissue sarcoma. Studies indicate that it does not increase the risk of side effects compared to traditional longer courses of radiotherapy, and it may even improve treatment adherence and cost-effectiveness.12345
How is hypofractionated radiotherapy different from other treatments for soft tissue sarcoma?
Hypofractionated radiotherapy for soft tissue sarcoma is unique because it involves delivering higher doses of radiation over a shorter period, typically in 5 sessions, compared to the conventional 5-week schedule. This approach may improve patient adherence, reduce costs, and offer more treatment opportunities without increasing side effects or compromising effectiveness.12345
What data supports the effectiveness of the treatment Intensive Pre-Operative Radiotherapy for Soft Tissue Sarcoma?
Who Is on the Research Team?
Fabio Cury, MD
Principal Investigator
Research Institute of McGill University Health Centre
Are You a Good Fit for This Trial?
This trial is for adults over 18 with a specific type of cancer called soft tissue sarcoma, located above the knee or in the trunk. Candidates must have a tumor that can be surgically removed, no prior radiation therapy, and an ECOG score of 0-2 indicating they are relatively active. They cannot participate if they have other cancers (except certain skin cancers), lymph node involvement by cancer, previous radiation in the area to be treated, or major illnesses.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-treatment Evaluation
Standard pre-treatment evaluation including history, physical exam, radiology, and quality of life assessments
Radiation Treatment
Hypofractionated radiotherapy delivering five fractions of 7 Gy over one and a half weeks
Surgery
Surgery performed 4-6 weeks after completion of radiotherapy
Follow-up
Participants are monitored for acute and late toxicity, wound assessment, and quality of life
What Are the Treatments Tested in This Trial?
Interventions
- Hypofractionation
Hypofractionation is already approved in European Union, United States, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor